Article
Oncology
Toni Choueiri, Camillo Porta, Cristina Suarez, John Hainsworth, Eric Voog, Ignacio Duran, James Reeves, Piotr Czaykowski, Daniel Castellano, Jingjing Chen, Farhad Sedarati, Thomas Powles
Summary: This study evaluated the efficacy and safety of single-agent sapanisertib and sapanisertib plus the PI3K alpha inhibitor TAK-117 versus everolimus in patients with advanced clear cell renal cell carcinoma that had progressed on or after VEGF-targeted therapy. The results showed that sapanisertib, with or without TAK-117, was not more effective than everolimus in improving outcomes in patients with relapsed or refractory advanced ccRCC, and had lower tolerability.
Article
Oncology
Michael Staehler, Michael Stoeckle, Daniel C. Christoph, Arnulf Stenzl, Karin Potthoff, Marc-Oliver Grimm, Dunja Klein, Johanna Harde, Fabian Bruning, Peter J. Goebell, Marinela Augustin, Frederik Roos, Iris Benz-Rud, Norbert Marschner, Viktor Gruenwald
Summary: The MARC-2 trial investigated clinical outcomes in metastatic renal cell carcinoma patients treated with everolimus after failure of VEGFR-TKI therapy, finding that patients aged >=65 years and patients with BMI >25 kg/m2 benefited most, with no new safety signals emerging.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C. Fan, Benjamin A. Gartrell, Oscar B. Goodman, Petros G. Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M. Tannir
Summary: The study results demonstrate that TelaE showed improved progression-free survival compared to PboE in patients with mRCC who had previously received treatment with VGEFR-targeted tyrosine kinase inhibitors and checkpoint inhibitors.
CLINICAL CANCER RESEARCH
(2022)
Article
Urology & Nephrology
Sumanta K. Pal, Javier Puente, Daniel Y. C. Heng, Hilary Glen, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Tudor Ciuleanu, Jae Lyun Lee, Kaisa Sunela, Karen O'Hara, Terri A. Binder, Lixian Peng, Alan D. Smith, Sun Young Rha
Summary: In patients with advanced renal cell carcinoma, a lower starting dose of lenvatinib (14 mg) did not show comparable efficacy to the approved dose (18 mg), although safety results were similar.
Article
Oncology
Chijioke Nze, Pavlos Msaouel, Mohamed H. Derbala, Bettzy Stephen, Abdulrahman Abonofal, Funda Meric-Bernstam, Nizar M. Tannir, Aung Naing
Summary: Renal medullary carcinoma (RMC) is a highly aggressive kidney cancer and traditional treatments are not effective. Inflammation was found in RMC tissues, suggesting that immune checkpoint therapies could be a potential treatment option. However, the study showed that pembrolizumab, an immune checkpoint inhibitor, did not have any clinical benefits in patients with RMC.
Article
Genetics & Heredity
Wang Yangyun, Shi Guowei, Shi Shufen, Yao Jie, Yu Rui, Ren Yu
Summary: The combination of Everolimus with RSL3 or Erastin demonstrates anti-tumor effects in RCC by synergistically inhibiting cell viability and inducing ferroptosis. Inhibition of the mTOR-4EBP1 axis is crucial for the synergistic effects. Forced expression of GPX4 can abrogate ferroptosis induced by the combination treatment, suggesting a promising therapeutic option for RCC.
Article
Oncology
Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Summary: In the METEOR phase 3 trial, cabozantinib demonstrated improved PFS and OS compared to everolimus in advanced RCC patients. Low baseline levels of HGF, AXL, and VEGF were prognostic for improvements with cabozantinib, while low HGF was prognostic for improvements with everolimus. Low AXL was predictive of relative PFS improvement with cabozantinib versus everolimus. Baseline HGF was consistently identified as a prognostic biomarker for improved outcomes with both treatments.
Article
Oncology
John A. Ligon, R. Taylor Sundby, Mary F. Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener, Ramaprasad Srinivasan, Melissa Spencer, Amanda Carbonell, Haiyan Lei, John Shern, Seth M. Steinberg, William D. Figg, Cody J. Peer, Sara Zimmerman, Josquin Moraly, Xia Xu, Stephen Fox, King Chan, Michael I. Barbato, Thorkell Andresson, Naomi Taylor, Karel Pacak, J. Keith Killian, Eva Dombi, W. Marston Linehan, Markku Miettinen, Richard Piekarz, Lee J. Helman, Paul Meltzer, Brigitte Widemann, John Glod
Summary: This study evaluated the clinical activity of guadecitabine, a dinucleotide containing the DNA methyltransferase inhibitor decitabine, in patients with dSDH-deficient tumors. The results showed that guadecitabine was well-tolerated, but no objective responses were observed.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Chung-Han Lee, Martin H. Voss, Maria Isabel Carlo, Ying-Bei Chen, Mark Zucker, Andrea Knezevic, Robert A. Lefkowitz, Natalie Shapnik, Chloe Dadoun, Ed Reznik, Neil J. Shah, Colette Ngozi Owens, Deaglan Joseph McHugh, David Henry Aggen, Andrew Leonard Laccetti, Ritesh Kotecha, Darren R. Feldman, Robert J. Motzer
Summary: Cabozantinib/nivolumab combination therapy shows promising efficacy in non-clear-cell renal cell carcinoma, particularly in variants with prominent papillary features, while the treatment effect is limited in chromophobe RCC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Shouki Bazarbashi, Ahmed Alzahrani, Ali Aljubran, Mahmoud Elshenawy, Ahmed Mostafa Gad, Fatima Maraiki, Noura Alzannan, Tusneem Elhassan, Ahmed Badran
Summary: This study aimed to test the alternating use of sunitinib and bevacizumab for advanced clear cell renal cell carcinoma patients. The results showed that adding bevacizumab to sunitinib treatment can continuously block angiogenesis and effectively inhibit tumor growth with manageable toxicity.
Article
Oncology
Philip Zeuschner, Sebastian Hoelters, Michael Stoeckle, Barbara Seliger, Anja Mueller, Hagen S. Bachmann, Viktor Gruenwald, Daniel C. Christoph, Arnulf Stenzl, Marc-Oliver Grimm, Fabian Bruening, Peter J. Goebell, Marinela Augustin, Frederik Roos, Johanna Harde, Iris Benz-Rued, Michael Staehler, Kerstin Junker
Summary: In patients with metastatic renal cell carcinoma treated with the mTOR inhibitor everolimus, lower levels of TSP-2 and higher levels of LDH were found to be predictive blood biomarkers associated with therapy response. These biomarkers had higher predictive value than baseline patient parameters or risk classifications, highlighting the need for predictive biomarkers in mRCC therapy. Polymorphisms in the mTOR gene may be associated with therapy response, but further research is needed to confirm this finding.
Article
Genetics & Heredity
Seong-Hwi Hong, Kwang-Suk Lee, Hyun-Ji Hwang, Sung-Yul Park, Woong-Kyu Han, Young-Eun Yoon
Summary: This study investigated the possibility of using a combination of everolimus and metformin as an effective treatment for RCC. The results showed that the combination treatment significantly inhibited RCC cell viability, migration, and invasion, and increased apoptosis. Transcriptome analysis revealed that the combination treatment disrupted mitochondrial dynamics. Overall, the combination of everolimus and metformin may be a novel strategy for RCC treatment by disrupting mitochondrial dynamics.
Article
Oncology
Zizhen Feng, Brendan D. Curti, David I. Quinn, John M. Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M. Beer, Christopher W. Ryan
Summary: This study assessed the efficacy of combining Sunitinib and Erlotinib in the treatment of advanced renal cell carcinoma. The results showed that the combination therapy did not provide better outcomes in terms of 8-month progression-free survival rate compared to Sunitinib monotherapy.
CLINICAL GENITOURINARY CANCER
(2022)
Article
Oncology
Pedro C. Barata, Alexander Chehrazi-Raffle, Kimberly D. Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K. Pal
Summary: This article reports on the efficacy of Tivozanib in histologically diverse non-clear cell renal cell carcinoma. The study found that Tivozanib demonstrated activity and a favorable safety profile in patients with non-clear cell renal cell carcinoma, adding to the evidence supporting the use of VEGFR-TKI in this type of cancer.
Article
Medicine, General & Internal
Christopher W. Ryan, Catherine M. Tangen, Elisabeth Heath, Mark N. Stein, Maxwell Meng, Ajjai S. Alva, Sumanta K. Pal, Igor Puzanov, Joseph Clark, Toni K. Choueiri, Neeraj Agarwal, Robert G. Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Ian M. Thompson Jr, Primo N. Lara Jr
Summary: Postoperative administration of everolimus did not show improvement in recurrence-free survival compared to placebo for renal cell carcinoma patients at high risk of recurrence after nephrectomy. These results do not provide support for the adjuvant use of everolimus in the treatment of renal cell carcinoma following surgery.